Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

DPYD Antikörper

DPYD Reaktivität: Human WB, ELISA, IHC Wirt: Kaninchen Polyclonal unconjugated
Produktnummer ABIN7178655
  • Target Alle DPYD Antikörper anzeigen
    DPYD (Dihydropyrimidine Dehydrogenase (DPYD))
    Reaktivität
    • 44
    • 15
    • 13
    • 1
    • 1
    • 1
    Human
    Wirt
    • 44
    • 2
    Kaninchen
    Klonalität
    • 43
    • 3
    Polyklonal
    Konjugat
    • 21
    • 3
    • 3
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    Dieser DPYD Antikörper ist unkonjugiert
    Applikation
    • 34
    • 14
    • 13
    • 13
    • 8
    • 6
    • 3
    • 3
    • 3
    • 1
    • 1
    • 1
    Western Blotting (WB), ELISA, Immunohistochemistry (IHC)
    Kreuzreaktivität
    Human, Maus, Ratte
    Aufreinigung
    Affinity purification
    Immunogen
    Recombinant protein of Human DPYD
    Isotyp
    IgG
    Top Product
    Discover our top product DPYD Primärantikörper
  • Applikationshinweise
    WB:1:500-1:2000, IHC:1:50-1:200,
    Beschränkungen
    Nur für Forschungszwecke einsetzbar
  • Format
    Liquid
    Buffer
    Store at -20 °C or -80 °C. Avoid freeze / thaw cycles. Buffer: PBS with 0.02 % sodium azide, 50 % glycerol, pH 7.3.
    Konservierungsmittel
    Sodium azide
    Vorsichtsmaßnahmen
    This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    Lagerung
    -20 °C,-80 °C
    Informationen zur Lagerung
    Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
  • Target
    DPYD (Dihydropyrimidine Dehydrogenase (DPYD))
    Andere Bezeichnung
    DPYD (DPYD Produkte)
    Hintergrund

    Background: Dihydropyrimidine dehydrogenase (DPD, DPYD) catalyzes the initial and rate-limiting step in uracil and thymidine catabolism as well as catabolism of the chemotherapeutic drug 5-fluorouracil (5-FU) and its derivatives. DPYD deficiency, which results from mutations in the DPYD gene, causes errors in pyrimidine metabolism and potentially life-threatening side effects in cancer patients treated with 5-FU (reviewed in 1). As a result, ongoing work examines whether or how DPYD gene variation and protein expression can be used to predict 5-FU toxicity. Several genes that impart resistance to 5-FU were recently identified in human hepatocellular carcinoma (HCC). AEG-1, which is highly expressed in HCC, increases the expression of DPYD. DPYD is expressed more highly in HCC than in normal liver, and this is thought to be one mechanism of 5-FU resistance.

    Aliases: DHP antibody, DHPDHase antibody, Dihydropyrimidine dehydrogenase [NADP(+)] antibody, Dihydropyrimidine dehydrogenase [NADP+] antibody, Dihydropyrimidine dehydrogenase antibody, Dihydrothymine dehydrogenase antibody, Dihydrouracil dehydrogenase antibody, DPD antibody, DPYD antibody, DPYD_HUMAN antibody, MGC132008 antibody, MGC70799 antibody, OTTHUMP00000058954 antibody

    UniProt
    Q12882
    Pathways
    Ribonucleoside Biosynthetic Process
Kundenservice